Article Information
History
- April 6, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Xuan Wang, MD, MSc1,
- Katrin Haeussler, PhD, MSc2,
- Anne Spellman, PhD, MSc3,
- Leslie E. Phillips, PhD, SM4,
- Allison Ramiller, MPH4,
- Mary T. Bausch-Jurken, PhD, MS5,
- Pawana Sharma, MSc6,
- Anna Krivelyova, MA6,
- Sonam Vats, MPG7 and
- Nicolas Van de Velde, PhD5,*
- 1ICON plc, Stockholm, Sweden;
- 2ICON plc, Munich, Germany;
- 3Data Health Ltd, London, United Kingdom;
- 4Data–Driven LLC, Seattle, WA, United States;
- 5Moderna, Inc., Cambridge, MA, United States;
- 6ICON plc, London, United Kingdom;
- 7ICON plc, Bengaluru, India
- ↵*Address correspondence to: Nicolas Van de Velde, PhD Moderna, Inc. 200 Technology Square, Cambridge, MA 02139 Phone: (617) 417-3593 Email: Nicolas.VandeVelde{at}modernatx.com Running head: COVID-19 Vaccine Effectiveness: Immunocompromised Individuals
Posted April 06, 2023.
Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines in Immunocompromised Individuals: A Systematic Review and Meta-Analysis Using the GRADE Framework
